TY  - JOUR
AU  - Martín, Miguel
AU  - Chacón, José I
AU  - Antón, Antonio
AU  - Plazaola, Arrate
AU  - García-Martínez, Elena
AU  - Seguí, Miguel A
AU  - Sánchez-Rovira, Pedro
AU  - Palacios, José
AU  - Calvo, Lourdes
AU  - Esteban, Carmen
AU  - Espinosa, Enrique
AU  - Barnadas, Agusti
AU  - Batista, Norberto
AU  - Guerrero, Angel
AU  - Muñoz, Montserrat
AU  - Romio, Estefania
AU  - Rodríguez-Martín, César
AU  - Caballero, Rosalía
AU  - Casas, María I
AU  - Rojo, Federico
AU  - Carrasco, Eva
AU  - Antolín, Silvia
PY  - 2017
DO  - 10.1634/theoncologist.2017-0052
UR  - http://hdl.handle.net/10668/11399
T2  - The oncologist
AB  - Nanoparticle albumin-bound paclitaxel (nab-Paclitaxel) is an alternative to standard taxanes for breast cancer (BC) treatment. We evaluated nab-Paclitaxel efficacy as neoadjuvant treatment for early estrogen receptor-positive (ER+), human epidermal...
LA  - en
KW  - Estrogen receptor‐positive breast cancer
KW  - Luminal breast cancer
KW  - Nanoparticle albumin‐bound Paclitaxel
KW  - Neoadjuvant treatment
KW  - Residual cancer burden
KW  - Adult
KW  - Aged
KW  - Albumin-Bound Paclitaxel
KW  - Breast Neoplasms
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Estrogen Receptor alpha
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Nanoparticles
KW  - Receptor, ErbB-2
TI  - Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
TY  - research article
VL  - 22
ER  -